These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC. Gupta S; Swanson AA; Chen YB; Lopez T; Milosevic D; Kipp BR; Leibovich BC; Thompson RH; Herrera-Hernandez L; Cheville JC; Jimenez RE Hum Pathol; 2019 Sep; 91():114-122. PubMed ID: 31299266 [TBL] [Abstract][Full Text] [Related]
5. Immunoexpression of SDHB, FH, and CK20 among eosinophilic renal tumors: A tissue microarray study. Karatay H; Ozluk Y; Dogan MA; Erdem S; Kilicaslan I Ann Diagn Pathol; 2021 Oct; 54():151788. PubMed ID: 34246177 [TBL] [Abstract][Full Text] [Related]
6. Fumarate hydratase as a therapeutic target in renal cancer. Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123 [TBL] [Abstract][Full Text] [Related]
7. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma. Sun G; Zhang X; Liang J; Pan X; Zhu S; Liu Z; Armstrong CM; Chen J; Lin W; Liao B; Lin T; Huang R; Zhang M; Zheng L; Yin X; Nie L; Shen P; Zhao J; Zhang H; Dai J; Shen Y; Li Z; Liu J; Chen J; Liu J; Wang Z; Zhu X; Ni Y; Qin D; Yang L; Chen Y; Wei Q; Li X; Zhou Q; Huang H; Yao J; Chen N; Zeng H Clin Cancer Res; 2021 Mar; 27(6):1734-1743. PubMed ID: 33414138 [TBL] [Abstract][Full Text] [Related]
8. Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy. Ueno D; Vasquez JC; Sule A; Liang J; van Doorn J; Sundaram R; Friedman S; Caliliw R; Ohtake S; Bao X; Li J; Ye H; Boyd K; Huang RR; Dodson J; Boutros P; Bindra RS; Shuch B Oncotarget; 2022; 13():1054-1067. PubMed ID: 36128328 [TBL] [Abstract][Full Text] [Related]
9. The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes. Udager AM; Magers MJ; Goerke DM; Vinco ML; Siddiqui J; Cao X; Lucas DR; Myers JL; Chinnaiyan AM; McHugh JB; Giordano TJ; Else T; Mehra R Hum Pathol; 2018 Jan; 71():47-54. PubMed ID: 29079178 [TBL] [Abstract][Full Text] [Related]
10. Increased HIF1 alpha in SDH and FH deficient tumors does not cause microsatellite instability. Lehtonen HJ; Mäkinen MJ; Kiuru M; Laiho P; Herva R; van Minderhout I; Hogendoorn PC; Cornelisse C; Devilee P; Launonen V; Aaltonen LA Int J Cancer; 2007 Sep; 121(6):1386-9. PubMed ID: 17520677 [TBL] [Abstract][Full Text] [Related]
11. Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma. Ohe C; Smith SC; Sirohi D; Divatia M; de Peralta-Venturina M; Paner GP; Agaimy A; Amin MB; Argani P; Chen YB; Cheng L; Colecchia M; Compérat E; Werneck da Cunha I; Epstein JI; Gill AJ; Hes O; Hirsch MS; Jochum W; Kunju LP; Maclean F; Magi-Galluzzi C; McKenney JK; Mehra R; Nesi G; Osunkoya AO; Picken MM; Rao P; Reuter VE; de Oliveira Salles PG; Schultz L; Tickoo SK; Tomlins SA; Trpkov K; Amin MB Am J Surg Pathol; 2018 Mar; 42(3):279-292. PubMed ID: 29309300 [TBL] [Abstract][Full Text] [Related]
12. Review of succinate dehydrogenase-deficient renal cell carcinoma with focus on clinical and pathobiological aspects. Kuroda N; Yorita K; Nagasaki M; Harada Y; Ohe C; Jeruc J; Raspollini MR; Michal M; Hes O; Amin MB Pol J Pathol; 2016 Mar; 67(1):3-7. PubMed ID: 27179267 [TBL] [Abstract][Full Text] [Related]
13. SDHB-Deficient Cancers: The Role of Mutations That Impair Iron Sulfur Cluster Delivery. Saxena N; Maio N; Crooks DR; Ricketts CJ; Yang Y; Wei MH; Fan TW; Lane AN; Sourbier C; Singh A; Killian JK; Meltzer PS; Vocke CD; Rouault TA; Linehan WM J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26719882 [TBL] [Abstract][Full Text] [Related]
14. Fumarate hydratase deficient renal cell carcinoma and fumarate hydratase deficient-like renal cell carcinoma: Morphologic comparative study of 23 genetically tested cases. Pivovarčíková K; Martínek P; Trpkov K; Alaghehbandan R; Magi-Galluzzi C; Mundo EC; Berney D; Suster S; Gill A; Rychlý B; Michalová K; Pitra T; Hora M; Michal M; Hes O Cesk Patol; 2019; 55(4):244-249. PubMed ID: 31842557 [TBL] [Abstract][Full Text] [Related]
15. Low-grade Oncocytic Fumarate Hydratase-deficient Renal Cell Carcinoma: An Update on Biologic Potential, Morphologic Spectrum, and Differential Diagnosis With Other Low-grade Oncocytic Tumors. Hamza A; Sirohi D; Smith SC; Amin MB Adv Anat Pathol; 2021 Nov; 28(6):396-407. PubMed ID: 34561376 [TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and molecular features of hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinomas. Furuya M; Iribe Y; Nagashima Y; Kambe N; Ohe C; Kinoshita H; Sato C; Kishida T; Okubo Y; Numakura K; Nanjo H; Nakaigawa N; Makiyama K; Hasumi H; Iwashita H; Ohta J; Kitamura H; Nakajima T; Yoshida T; Nakagawa M; Tanaka R; Yao M J Clin Pathol; 2020 Dec; 73(12):819-825. PubMed ID: 32376712 [TBL] [Abstract][Full Text] [Related]
17. Renal cell carcinoma in young FH mutation carriers: case series and review of the literature. Hol JA; Jongmans MCJ; Littooij AS; de Krijger RR; Kuiper RP; van Harssel JJT; Mensenkamp A; Simons M; Tytgat GAM; van den Heuvel-Eibrink MM; van Grotel M Fam Cancer; 2020 Jan; 19(1):55-63. PubMed ID: 31792767 [TBL] [Abstract][Full Text] [Related]
18. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach. Wyvekens N; Valtcheva N; Mischo A; Helmchen B; Hermanns T; Choschzick M; Hötker AM; Rauch A; Mühleisen B; Akhoundova D; Weber A; Moch H; Rupp NJ Genes Chromosomes Cancer; 2020 Nov; 59(11):611-619. PubMed ID: 32537760 [TBL] [Abstract][Full Text] [Related]